Aarti Drugs AGM approves new director appointments and FY26 financials
- Aarti Drugs Limited held its 41st AGM on September 26, 2026, approving new director appointments including Niles Bhalchandra Patil and Adhish Prakash Patil.
- FY26 consolidated revenue rose 7% YoY to ₹2,568 crore, while PAT increased 16% YoY to ₹195 crore.
- Q1FY27 results showed strong momentum with revenue up 19% YoY to ₹704 crore and EBITDA up 30% YoY to ₹97 crore.
- The company invested ₹200 crore in oncology development and received USFDA approval for its oncology facility in FY26.
*this image is generated using AI for illustrative purposes only.
Aarti Drugs Limited held its 41st Annual General Meeting on September 26, 2026, where shareholders approved several key appointments and adopted the audited financial statements for FY26. The meeting also featured an investor presentation highlighting strategic growth initiatives.
The meeting, conducted via Video Conferencing, saw 93 members participate. The agenda included the adoption of standalone and consolidated financial statements for the year ended March 31, 2026, alongside reports from the Board of Directors and Auditors. Shareholders also approved the "Aarti Drugs Limited Performance Stock Option Plan 2026" (PSOP 2026), which includes provisions for granting stock options to employees of subsidiary, group, and associate companies.
Leadership changes approved
Shareholders voted in favor of multiple resolutions concerning the company's board composition. The appointments mark a significant shift in the executive leadership structure.
| Resolution | Details |
|---|---|
| Appointment | Niles Bhalchandra Patil as Director and Whole-time Director |
| Appointment | Adhish Prakash Patil as Director and Managing Director |
| Re-appointment | Harshit Manilal Savla as Joint Managing Director |
| Re-appointment | Harit Pragji Shah as Whole-time Director |
Additionally, the re-appointment of three Independent Directors for a second term of five years was approved. These include Hasmukh Bhavanji Dedhia, Sandeep Madhusudan Joshi, and Ajit Eledath Venugopalan.
Financial performance highlights
The investor presentation disclosed consolidated financial results for FY26 and Q1FY27. For FY26, total revenue rose 7% YoY to ₹2,568 crore, while EBITDA increased to ₹312 crore with a margin of 12.1%. Profit after tax (PAT) grew 16% YoY to ₹195 crore, with PAT margin expanding to 7.6%.
| Metric | FY25 | FY26 | Growth |
|---|---|---|---|
| Total Revenue (₹ crore) | 2,403 | 2,568 | +7% |
| EBITDA (₹ crore) | 304 | 312 | +3% |
| PAT (₹ crore) | 168 | 195 | +16% |
Q1FY27 results showed stronger momentum, with revenue rising 19% YoY to ₹704 crore and EBITDA jumping 30% YoY to ₹97 crore. PBT increased 35% YoY to ₹69 crore.
| Metric | Q1 FY26 | Q1 FY27 | YoY Growth |
|---|---|---|---|
| Revenue (₹ crore) | 591 | 704 | +19% |
| EBITDA (₹ crore) | 74 | 97 | +30% |
| PBT (₹ crore) | 51 | 69 | +35% |
Strategic growth and capacity expansion
The presentation outlined a strategic pivot toward scaling regulated market sales through the expansion of formulations and oncology product portfolios. The company has invested ₹200 crore over the last 24 months solely for oncology development. Key regulatory approvals received in FY26 include USFDA approval for the oncology facility and UK MHRA approval for the oral solid dosage (OSD) facility.
Capacity expansion remains a core focus. The Sayakha methylamines facility has been commissioned to strengthen backward integration for the Metformin portfolio. Installed capacity increased from 61,053 MT in FY25 to 82,512 MT in FY26. The company plans to scale anti-diabetic capacity from ~1,400 TPM to 2,000–2,200 TPM, with additional brownfield expansions underway.
What the numbers show
While FY26 revenue growth was modest at 7%, driven largely by volume gains of 7% offsetting a 3% price degrowth, Q1FY27 indicates a sharper recovery. The 19% revenue jump in Q1FY27 suggests that pricing stabilization is beginning to reflect in top-line performance. Furthermore, the shift in segment mix shows Speciality Chemicals growing to 11.7% of revenue in Q1FY27 from 7.0% in FY26, indicating successful diversification beyond traditional APIs.
Other shareholder approvals
Other passed resolutions included payment of profit-related commission to non-executive directors, approval for Prakash Moreshwar Patil to hold an office or place of profit, and ratification of remuneration for cost auditors for FY27. The meeting commenced at 11:00 am and concluded at 11:57 am. Remote e-voting facilities were available from September 23 to September 25, 2026.
Historical Stock Returns for Aarti Drugs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.25% | -0.22% | +1.51% | +27.41% | -17.36% | -30.37% |
How will the new leadership structure under Managing Director Adhish Prakash Patil specifically influence the execution timeline of the oncology portfolio expansion?
What are the projected capital expenditure requirements to achieve the target anti-diabetic capacity of 2,000–2,200 TPM, and how will this impact future free cash flow?
Can the company sustain the 30% EBITDA growth seen in Q1FY27 throughout the fiscal year, or is this driven by temporary pricing stabilization?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
